Neurobiological Technologies Inc.
2000 Powell Street
Suite 800
Emeryville,
CA 94608
United States - Map
Phone: 510-595-6000
Fax: 510-595-6006
Web Site: http://www.ntii.com
| Neurobiological Technologies, Inc., a biopharmaceutical company, engages in acquisition and development of central nervous system related drug candidates. Its advanced product candidate, Viprinex, is in Phase III clinical testing for treatment of acute ischemic stroke. The company has a strategic research and marketing cooperation agreement with Merz and Childrens Medical Center Corporation for the clinical development and commercialization of memantine; and collaboration and services agreement with Celtic Pharma Holdings, L.P. for the development of XERECEPT, a Phase III clinical trial product for the treatment of swelling associated with brain tumors. Neurobiological Technologies also has collaboration and license agreements with the Buck Institute for Age Research for the development of proteins in preclinical development for the treatment of Alzheimers and Huntingtons diseases. The company was founded in 1987 and is based in Emeryville, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Bill Fletcher , 61
Acting Chief Exec. Officer, Director, Chairman of Special Committee and Member of Nominating & Corp. Governance Committee |
$
30.00K |
$
0 | Mr. John B. Stuppin , 75
Founder, Director, Chairman of Nominating & Corp. Governance Committee and Member of Special Committee |
$
90.00K | N/A | Mr. Matthew M. Loar , 46
Chief Financial Officer, Principal Accounting Officer and VP |
$
335.00K |
$
0 | Dr. Enoch Callaway M.D., 85
Founder Emeritus |
N/A
| N/A | Mr. Stephen Ferruolo J.D., Ph.D.,
Sec. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.17% Nasdaq 
0.0096 (1.04%) 
Profile
